Clinical trials: Teriflunomide
Relapsing Remitting Multiple Sclerosis
Mechanistic Studies of Teriflunomide in RRMS
This study is to address the mechanism of action of teriflunomide in a phase IV open label trial with Teriflunomide in multiple sclerosis.
- Trial name
- NCT03464448
- Testing
- Teriflunomide
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Teriflunomide Elimination, Healthy Volunteers
Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride
Primary Objective To determine if colestipol hydrochloride tablets can accelerate the elimination of teriflunomide. Teriflunomide will be administered for 14 days followed by colestipol dosing of 11 days.
- Trial name
- TERCOL (NCT02263547)
- Testing
- teriflunomide, Colestipol
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Derrick Scott Robertson
Multiple Sclerosis
Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
Primary Objective: To measure the effect of Teriflunomide on lymphocytes subsets in patients with relapsing forms of multiple sclerosis as compared with baseline values and those of a reference population of untreated healthy…
- Trial name
- TERI-DYNAMIC (NCT01863888)
- Testing
- teriflunomide HMR1726, cholestyramine, charcoal
- Where
- 10 sites in Belgium, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis
A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers
Primary Objective: To assess the pharmacokinetic (PK) parameters of teriflunomide after a single oral dose of 14 mg administration in Chinese healthy subjects Secondary Objective: To assess the safety and tolerability after a…
- Trial name
- NCT02046629
- Testing
- Teriflunomide HMR1726, cholestyramine
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis, Relapsing-Remitting
Cognition and MRI Markers in MS Patients With Aubagio® Treatment
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease which contributes largely to disability.
- Trial name
- AUBACOG (NCT03768648)
- Testing
- Clinical assessment, Ecological evaluation, Neuropsychological evaluation
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Multiple Sclerosis, Relapsing-Remitting
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)
The study is a two-year prospective observational study of patients treated with teriflunomide. The investigators will recruit up to 75 patients at baseline, based on the estimate that approximately 20% of these patients (~ 15…
- Trial name
- NCT03561402
- Testing
- Teriflunomide
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- McGill University
Multiple Sclerosis
An Observational Study on Teriflunomide-exposed Pregnancies
Primary Objective: To evaluate any potential increase in the risk of major birth defects, in the first year of life, in teriflunomide-exposed pregnancies.
- Trial name
- NCT03198351
- Testing
- Teriflunomide (HMR1726)
- Where
- 2 sites in United States, Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis
Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months
This study will evaluate the effects of Aubagio on changes in the brain using MRI.
- Trial name
- GZA (NCT01881191)
- Testing
- MRI
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Multiple Sclerosis
Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis
Cognitive impairment is common in MS and has devastating impact on functional activities. There is a great demand for medications that will enhance cognitive capacity in MS patients.
- Trial name
- NCT02651545
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo